Biogen, Inc.-Product Pipeline Review-2015

Biogen, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC06950CDB
  • |
  • Pages: 86
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Biogen, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Biogen, Inc.-Product Pipeline Review-2015', provides an overview of the Biogen, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biogen, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Biogen, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Biogen, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Biogen, Inc.'s pipeline products

Reasons To Buy

Evaluate Biogen, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Biogen, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Biogen, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Biogen, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biogen, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Biogen, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Biogen, Inc. Snapshot 7

Biogen, Inc. Overview 7

Key Information 7

Key Facts 7

Biogen, Inc.-Research and Development Overview 8

Key Therapeutic Areas 8

Biogen, Inc.-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Pipeline Products-Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products-Out-Licensed Products 16

Out-Licensed Products/Combination Treatment Modalities 17

Biogen, Inc.-Pipeline Products Glance 18

Biogen, Inc.-Late Stage Pipeline Products 18

Pre-Registration Products/Combination Treatment Modalities 18

Phase III Products/Combination Treatment Modalities 19

Biogen, Inc.-Clinical Stage Pipeline Products 20

Phase II Products/Combination Treatment Modalities 20

Phase I Products/Combination Treatment Modalities 21

Biogen, Inc.-Early Stage Pipeline Products 22

Preclinical Products/Combination Treatment Modalities 22

Biogen, Inc.-Drug Profiles 23

antihemophilic factor (recombinant), fc fusion protein 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

natalizumab 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

rituximab 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

aducanumab 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

BG-00010 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

BIIB-023 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

opicinumab 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

STX-100 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Antibodies to Activate BCAD2 for Systematic Lupus Erthematosus 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

BG-00001 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

BIIB-059 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

BIIB-061 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

5D-10 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

BIIB-053 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

BIIB-054 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Gene Therapy for Hemophilia A and B 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Monoclonal Antibodies to Inhibit Alpha Synuclein for Neurodegenerative Diseases 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Monoclonal Antibody to Inhibit TDP-43 for Neurodegenerative Diseases 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

NI-105 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

NI-205 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Recombinant Protein to Agonize GM-CSFR for Alzheimer's disease and Brain Injury 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Recombinant Protein to Replace Factor VIII for Hemophilia A 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Small Molecules to Activate Glucosylceramidase for Parkinson's Disease 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Biogen, Inc.-Pipeline Analysis 55

Biogen, Inc.-Pipeline Products by Target 55

Biogen, Inc.-Pipeline Products by Route of Administration 57

Biogen, Inc.-Pipeline Products by Molecule Type 58

Biogen, Inc.-Pipeline Products by Mechanism of Action 59

Biogen, Inc.-Recent Pipeline Updates 61

Biogen, Inc.-Dormant Projects 73

Biogen, Inc.-Discontinued Pipeline Products 75

Discontinued Pipeline Product Profiles 75

baminercept alfa 75

clenoliximab 75

CNF-1010 75

dexpramipexole dihydrochloride 75

naxifylline 76

Biogen, Inc.-Company Statement 77

Biogen, Inc.-Locations And Subsidiaries 79

Head Office 79

Other Locations & Subsidiaries 79

Biogen, Inc.-Key Manufacturing Facilities 84

Appendix 85

Methodology 85

Coverage 85

Secondary Research 85

Primary Research 85

Expert Panel Validation 85

Contact Us 85

Disclaimer 86

List of Tables

Biogen, Inc., Key Information 7

Biogen, Inc., Key Facts 7

Biogen, Inc.-Pipeline by Indication, 2015 9

Biogen, Inc.-Pipeline by Stage of Development, 2015 11

Biogen, Inc.-Monotherapy Products in Pipeline, 2015 12

Biogen, Inc.-Partnered Products in Pipeline, 2015 13

Biogen, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 14

Biogen, Inc.-Out-Licensed Products in Pipeline, 2015 16

Biogen, Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 17

Biogen, Inc.-Pre-Registration, 2015 18

Biogen, Inc.-Phase III, 2015 19

Biogen, Inc.-Phase II, 2015 20

Biogen, Inc.-Phase I, 2015 21

Biogen, Inc.-Preclinical, 2015 22

Biogen, Inc.-Pipeline by Target, 2015 56

Biogen, Inc.-Pipeline by Route of Administration, 2015 57

Biogen, Inc.-Pipeline by Molecule Type, 2015 58

Biogen, Inc.-Pipeline Products by Mechanism of Action, 2015 60

Biogen, Inc.-Recent Pipeline Updates, 2015 61

Biogen, Inc.-Dormant Developmental Projects,2015 73

Biogen, Inc.-Discontinued Pipeline Products, 2015 75

Biogen, Inc., Other Locations 79

Biogen, Inc., Subsidiaries 80

Biogen, Inc., Key Manufacturing Facilities 84

List of Figures

Biogen, Inc.-Pipeline by Top 10 Indication, 2015 9

Biogen, Inc.-Pipeline by Stage of Development, 2015 11

Biogen, Inc.-Monotherapy Products in Pipeline, 2015 12

Biogen, Inc.-Partnered Products in Pipeline, 2015 13

Biogen, Inc.-Out-Licensed Products in Pipeline, 2015 16

Biogen, Inc.-Pipeline by Top 10 Target, 2015 55

Biogen, Inc.-Pipeline by Top 10 Route of Administration, 2015 57

Biogen, Inc.-Pipeline by Top 10 Molecule Type, 2015 58

Biogen, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 59

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Biogen, Inc.; Biogen, Inc. - Key Therapeutics; Biogen, Inc. - Pipeline Overview and Promising Molecules; Biogen, Inc. - News; Biogen, Inc. - Latest Updates; Biogen, Inc. - Pipeline; Biogen, Inc. - Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 107220
Site License
USD 3000 INR 214440
Corporate User License
USD 4500 INR 321660



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]